Neovacs seeks partners for its clinical development

Neovacs, a preclinical biopharmaceutical company, announces a valuation of its mRNA program in severe asthma. This evaluation, carried out by In Extenso Innovation Croissance, estimates the value of the program at between €56 million and €98 million, with a growth potential of up to €402 million after successful clinical studies. The development of these trials would require €17 million.

Despite its ability to invest this amount, Neovacs is looking for partners to share costs and risks. The company has initiated contacts in Europe and the United States to attract potential collaborations. Future announcements regarding these steps will be communicated at a later date.